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Summary
Background.— Previous studies have shown protective effects of brain natriuretic peptide (BNP)
against the postmyocardial infarction (MI) remodelling process. The transcription factor NF-B
is known to play an important role after MI.metalloproteinase;
NF-B;
Myocardial
infarction;
Remodelling
Aims.— To investigate if NF-B is involved in the protective effects of BNP against adverse
post-MI remodelling.
Methods.— Rats were randomly assigned to ﬁve groups: sham-operation; MI by coronary lig-
ation; MI treated with chronic BNP infusion; MI treated with enalapril; MI treated with
BNP + enalapril. Rats were closely monitored for survival rate analysis. Rats from each group
were sacriﬁced on days 3, 7 and 28 postoperation.
 These authors contributed equally to this article.
Abbreviations: Ang II, angiotensin II; ANOVA, analysis of variance; BNP, brain natriuretic peptide; cGMP, cyclic guanosine
monophosphate; CVF, collagen volume fraction; FS, fractional shortening; IL, interleukin; LAD, left anterior descending; LSD, least
signiﬁcant difference; LV, left ventricle/ventricular; LVEDD, left ventricular end-diastolic diameter; LVEDP, left ventricular end-diastolic
pressure; LVESD, left ventricular end-systolic diameter; LVW/BW, left ventricular weight/body weight; MAP, mean arterial pressure; MI,
myocardial infarction; MMP, matrix metalloproteinase; NPRA, natriuretic peptide receptor A; p, phosphorylated; TGF, transforming growth
factor; TNF, tumour necrosis factor; TIMP, tissue inhibitor of metalloproteinase.
∗ Corresponding author. Fax: +86 21 64369181 ext 8721.
E-mail address: Weim.sjtu6h@hotmail.com (M. Wei).
1875-2136/$ — see front matter © 2010 Elsevier Masson SAS. All rights reserved.
doi:10.1016/j.acvd.2010.09.006
18 Y. Pan et al.
Results.— The results showed that chronic continuous BNP infusion achieved similar effects
to enalapril therapy, as evidenced by improved survival rate within the 28-day observation
period compared with MI group rats; this effect was closely associated with preserved cardiac
geometry and performance. The treatment combination did not offer extra beneﬁts in terms
of survival rate. Both BNP and enalapril therapy produced higher heart tissue concentrations of
cyclic guanosine monophosphate and lower expression levels of inﬂammatory cytokines, includ-
ing tumour necrosis factor-, interleukin-1 and interleukin-6. These beneﬁts were associated
with lower phosphorylation levels of NF-B subunits IB, p50 and p65. While enalapril signiﬁ-
cantly inhibited extracellular matrix remodelling via regulation of the protein expression ratio
of matrix metalloproteinase/tissue inhibitor of metalloproteinase and the activity of matrix
metalloproteinase, these variables were not affected by BNP, indicating that the two therapies
involve different mechanisms.
Conclusion.— Chronic BNP infusion can provide beneﬁcial effects against adverse post-MI
remodelling.
© 2010 Elsevier Masson SAS. All rights reserved.
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Résumé
Justiﬁcation.— Les travaux antérieurs ont montré l’effet protecteur du brain natriuretic pep-
tide (BNP) sur le remodelage post-infarctus du myocarde. Il a été montré que le NF-B, facteur
de transcription, avait un rôle important au décours d’un infarctus.
Objectifs.— Dans cette étude, l’objectif était d’évaluer l’implication du NF-B comme facteur
protecteur corrigeant le processus de remodelage, en utilisant un traitement par BNP. Les rats
ont été randomisés en premièrement témoins, deuxièmement groupe d’infarctus du myocarde
par ligature coronaire, troisièmement infarctus du myocarde recevant des perfusions du BNP
en chronique, quatrièmement infarctus du myocarde sous énalapril, cinquièmement infarctus
du myocarde traité par BNP et énalapril. Les animaux ont été monitorés, avec évaluation du
taux de survie. Tous les rats de cette étude expérimentale ont été sacriﬁés à j3, j7 et j28 après
l’intervention.
Résultats.— Comparativement aux rats ayant un infarctus du myocarde, la perfusion continue
de BNP s’accompagnait d’effets similaires à un traitement par énalapril comme cela a été
montré par une amélioration du taux de survie à j28, associés avec une préservation de la
géométrie ventriculaire gauche et de la fonction myocardique. Cependant, l’association de ces
deux traitements, BNP et énalapril n’a pas montré de bénéﬁce supplémentaire sur le taux de
survie. Cette association thérapeutique s’accompagnait d’une concentration tissulaire accrue
de cGMP, et une expression moindre des concentrations de cytokine inﬂammatoire incluant le
TNF-, l’IL-1 et l’IL-6. Ces bénéﬁces étaient associés avec un taux moindre de phosphorylation
des sous-unités NF-B, IB, P50 et P65. L’énalapril a inhibé de fac¸on signiﬁcative le remod-
elage de la matrice extracellulaire au travers d’une régulation de l’expression des protéines,
exprimée par le rapport métalloprotéinase de la matrice sur métalloprotéinase inhibitrice ainsi
que l’activité de la métalloprotéinase matricielle, cependant non affectée par la perfusion de
BNP, indiquant qu’il s’agirait de mécanismes différents pour le bénéﬁce observé de ces deux
molécules.
Conclusion.— La perfusion chronique du BNP peut provoquer des effets bénéﬁques pour corriger
s du
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ntroduction
NP, as an important natriuretic peptide secreted from
he ventricle, can act via the natriuretic peptide receptor
/guanylyl cyclase/cGMP signalling pathway, maintain-
ng cardiorenal homeostasis through diuresis, natriuresis,
asodilation and inhibition of aldosterone synthesis and
enin secretion under physiological and pathological con-
itions [1]. Release of the stored peptides due to altered
hamber loading and myocyte stretch [2] has been observed
n MI [3]. Interestingly, exogenous BNP infusion can protect
he heart-limiting infarct size in an ischaemia/reperfusion
B
f
Bmyocarde dans un modèle expérimental de rats.
s droits réservés.
njury rat model, possibly through adenosine triphosphate-
ensitive potassium channels and nitric oxide synthase
ctivation [4]. In addition, natriuretic peptide receptor
/cGMP signalling activated by BNP can modulate cardiac
esponses to hypertrophic stimuli and hence improve cardiac
emodelling via mediation of the calcineurin-nuclear factor
f activated T cells pathway [5,6], indicating that BNP also
lays an important role in the post-MI remodelling process.Previous studies have shown that intravenous infusion of
NP can improve clinical condition in patients with heart
ailure [7,8] and MI [9]. The long-term beneﬁcial effect of
NP therapy against ventricular remodelling has also been
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Figure 1. In panel A, a correlation curve was created for the
blood troponin I level obtained from 21 MIs and infarction size was
expressed as the percentage of necrosis/risk area, with a correla-
tion coefﬁcient of 0.979 (P < 0.05). In panel B, Kaplan-Meier curves
were created for the MI group, the MI + enalapril group, the MI + BNP
group and the MI + combination therapy group. All the rats were rig-
orously monitored for evaluation of survival rate. Both enalapril and
BNP infusion improved survival rate (P < 0.05, respectively) but no
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demonstrated in a rat MI model, which was associated with
inhibition of TGF1/Smad2 signalling [10]. However, it is
still not fully known how BNP infusion attenuates TGF
expression. NF-B is a key transcription factor that medi-
ates inﬂammatory cytokine expression in response to a
variety of stimuli [11], especially after MI [12]. Therefore,
using a rat MI model, we aimed to investigate whether
modulation of NF-B activity (and hence pro-inﬂammatory
cytokine expression) is involved in the improved remod-
elling process associated with chronic BNP infusion. The
beneﬁts of BNP infusion were compared with those of
the angiotensin-converting enzyme inhibitor enalapril, and
additive effects were tested when the two therapies were
combined.
Materials and methods
Male, 8-week-old Sprague-Dawly rats (Experimental Animal
Center, Fudan University, Shanghai, China) were used in this
study. The animal research study protocol complied with
The Guide for the Care of Use of Laboratory Animals pub-
lished by the National Institute of Health (NIH Publication
No. 85-23, revised 1996). All rats were housed for a 2-week
acclimatization period before the study started.
Animal preparation
The MI model was induced as described in our previous
report [13] by LAD coronary ligation. In brief, after anaes-
thesia with pentobarbital (50mg/kg, intraperitoneally) all
rats (weighing 320—380 g) underwent an open chest opera-
tion and the LAD coronary artery was encircled just distal
to its ﬁrst branch. The infarct was conﬁrmed by a pale area
below the suture or ST-T elevation on an electrocardiogram.
The control group underwent sham operation with passage
of a suture around the LAD without tie-down. All rats were
then allowed to recover under close observation.
Criteria for rat enrolment
To minimize the variability of infarct size, only rats with
moderate infarct size were enrolled. A pilot MI study was
performed on 21 rats. Twenty-four hours after LAD ligation,
blood serum was collected to measure troponin I concentra-
tion (Siemens Medical Solution Diagnostics, Tarrytown, NY,
USA). The heart was harvested from each rat and the LV was
cut into ﬁve parallel slices. Triphenyltetrazolium chloride
staining was performed and the extent of necrosis was quan-
tiﬁed by computerized planimetry. The total infarct size was
expressed as a percentage of the total sum of the infarct
area on each slice/LV corrected by weight. The correlation
curve was then derived for infarct size and serum troponin I
concentration (Fig. 1A) with an r value of 0.979 (P < 0.001).
An infarct size of 30—50% was arbitrarily selected as an
enrolment criterion, thus a blood serum troponin I concen-
tration of 28—47 g/L 24 hours after LAD ligation was set as
the inclusion criterion for MI rats. A total of 286 rats under-
went successful coronary ligation; 224 MI rats were enrolled
and 62 rats were excluded due to an inappropriate serum
troponin I concentration.
P
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aurther signiﬁcant beneﬁcial effects were obtained with combina-
ion therapy. *P < 0.05 vs MI group. BNP: brain natriuretic peptide;
TnI: cardiac troponin I; MI: myocardial infarction.
xperimental protocols
rotocol I
o evaluate survival rate, 160 MI rats with an appropriate
roponin I concentration were randomly assigned to one
f the following groups (n = 40 in each group): MI group;
I + enalapril group (1 day after LAD ligation, MI rats were
iven enalapril [Berlin-Chemie AG, Berlin, Germany] 10
g/kg/day by gavage); MI + BNP group (1 day after LAD
igation, MI rats were given continuous intravenous infu-
ion of rat-BNP-32 [Jingmei Biotech Co. Ltd., Shenzhen,
hina] 0.06 g/kg/minute through an osmotic mini-pump
Alza Corporation, Mountainview, CA, USA] [14] implanted
ntraperitoneally); MI + combination group (MI rats were
iven both the enalapril and BNP treatments). All MI rats
ere rigorously monitored to check the cause of sudden car-
iac death. A careful autopsy was performed for each rat
ith reference to cardiac rupture. Survival rate was anal-
sed to evaluate treatment beneﬁts.rotocol II
ime-course changes in the post-MI remodelling process
ere evaluated. The other 64 MI rats were then randomly
ssigned to the four groups (n = 16 to each group). Rats were
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acriﬁced on day 3 and day 7 after the MI (n = 8 for each time
oint), respectively.
Before the rats were sacriﬁced, echocardiography (ACU-
ON SEQUOIA 512 equipped with 14 MHz mini probe)
as performed, using the same anaesthesia as described
bove. Two-dimensional and M-mode echocardiograms were
btained. LVEDD and LVESD were measured in the short-axis
iew at papillary muscle level. FS was also obtained. All
alues were averages of three consecutive cardiac cycles
nd were analysed by two independent blinded researchers.
nvasive haemodynamic measurements were also taken by
ight carotid artery cannulation with a pre-heparinized ﬁne
olyethylene tube connected to a ﬂuid-ﬁlled pressure trans-
ucer (MPA-CFS, Alcott Biotech, Shanghai, China). After
uthanization, the heart from each rat was harvested. LV
eight was recorded for comparison with body weight, and
t papillary muscle level, one LV cross-sectional tissue slice
round 5mm in thickness was obtained, ﬁxed in 4% formalin
nd embedded in parafﬁn for the histological examination.
on-infarcted LV tissue was obtained from the rest of the LV,
nd was snap frozen in liquid nitrogen and stored at −80◦.
Eight rats that had completed 28 days of rigorous
bservation were randomly selected from each group and
nderwent the same procedure as described above.
Another 24 sham-operated control rats were also sacri-
ced on day 3, day 7 and day 28; these rats underwent the
ame procedure as described above.
uantiﬁcation of collagen deposition and infarct
ize
arafﬁn-embedded heart tissue was stained by Mallory’s
ethod, which is collagen speciﬁc. Three sections per
nimal and eight ﬁelds per section were scanned and com-
uterized with a Leica Q500MC digital image analyser at a
agniﬁcation of 10. The sections from different groups were
tained in one batch. CVF was obtained from the ratio of
he connective tissue area divided by the total tissue area
ithin the same microscopic ﬁeld. The infarct (expressed
s ﬁbrotic area) perimeter was traced and the size of
he MI was normalized to the LV area using the following
quation: percentage infarct perimeter = circumference of
nfarct scar/[(epicardium perimeter + endocardium perime-
er)/2]× 100%.
mmunohistochemistry
fter dewaxing, the sections of LV tissue of 5m thickness
ere immersed in 3% hydrogen peroxide for 10minutes at
oom temperature. After incubation with 5% bovine serum
lbumin (Boster, Wuhan, China) for 20minutes, the tis-
ue sections were probed with rabbit anti-rat type I and
ype III collagen antibodies (Boster, Wuhan, China) (1:100)
t 4◦C overnight. The sections were then incubated with
orseradish peroxidase-conjugated goat anti-rabbit anti-
ody (1:2000; Boster) for 30minutes at 37◦C then reacted
ith streptavidin-biotin-peroxidase complex (Boster) for
0minutes and coloured by diaminobenzaldehyde (Boster).
uantiﬁcation of resulting image data from immunohisto-
hemical staining was performed using a Leica Q500MC
igital image analyser.
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nzyme-linked immunosorbent assay
double-antibody sandwich-based enzyme-linked
mmunosorbent assay kit (USCN Life Science Inc., Wuhan,
hina) was used to detect angiotensin II (Ang II), cGMP, BNP,
NF, IL-1 and IL-6 concentrations in non-infarcted cardiac
issue, according to the manufacturer’s instructions. The
etection limits of each assay were as follows: Ang II,
.56 ng/mL; cGMP, 1.56 pmol/mL; BNP, 156 pg/mL; TNF,
.9 pg/mL; IL-1, 39 pg/mL; IL-6, 7.8 pg/mL. The intra- and
ntervariability for each kit were < 8%, respectively.
estern blotting
he detailed method of western blotting has been described
reviously using the rat MI model [15]. The primary antibod-
es against different proteins of MMP, including MMP-2 (R&D
ystems, Minneapolis, MN, USA), MMP-9, TIMP-1 (Abcam,
ambridge, MA, USA), phosphorylated (p)-NF-B-p50, NF-
B-p50 (Abcam, USA), p-IB- (Ser32), IB-, p-NF-B-p65
nd NF-B-p65 (Cell Signaling Technology, Danvers, MA,
SA), were used to probe the target protein. An antibody
gainst -actin (Santa Cruz Biotechnology Inc., Santa Cruz,
A, USA) was also used for protein loading. The bands for
ifferent proteins were quantiﬁed by densitometry using
mage J software (version 1.41, National Institutes of Health,
ethesda, MD, USA) and normalized to the expression of
-actin.
ymography
elatine zymography was used to determine MMP protein
ctivity as described. Approximately 10mg of myocardial
issue were extracted from the non-infarcted area and equal
olumes (10L) of samples normalized for protein concen-
ration were subjected to electrophoresis (without boiling or
eduction) through a 10% polyacrylamide gel co-polymerized
ith gelatine (0.5mg/mL), at 4◦C. After electrophoresis,
he gel was incubated for 1 hour at 25◦C in a 2.5% Tri-
on X-100 solution and then incubated overnight at 37 ◦C
n a 0.05M Tris-HCl buffer, pH 8.0, containing 5mM CaCl2.
he gels were ﬁxed with 40% methanol and 7% acetic acid,
tained with 0.25% Coomassie Brilliant Blue R250 and then
estained with 10% methanol and 7% acetic acid. The gels
ere scanned using the EagleEye II imaging system for rel-
tive lytic activity. A mixture of human MMP-2 and MMP-9
Chemicon, Hofheim, Germany) served as a zymography
tandard.
tatistical analysis
ll data are expressed as means± standard deviations.
aplan-Meier survival curves were analysed to check the
ifferences between MI rats with and without treatments.
ime-course changes in the haemodynamic heart tissue
xpression of MMP, cGMP, Ang II and BNP, and the extent
f ﬁbrosis were compared within groups by using repeated
NOVA measures, and between groups by using two-way
NOVA followed by LSD-corrected multiple comparisons.
ne-way ANOVA followed by LSD correction was used for
omparing the differences in all other variables between
roups. Non-parametric data were analysed using Fisher’s
xact method. A P-value < 0.05 was considered as sta-
istically signiﬁcant. Statistical analyses were performed
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using SPSS 13.0 statistics software (SPSS Inc., Chicago,
IL, USA).
Results
Survival rate
Troponin I values were similar in the four groups of
rats with MI (MI group, 35.8± 6.0 g/L; MI + enalapril
group, 33.6± 4.7 g/L; MI + BNP group, 36.8± 5.8 g/L;
MI + combination group, 37.0± 5.4 g/L), with no signiﬁcant
differences (P > 0.05, respectively). However, during the
28-day observation period, survival rates improved in
rats treated with BNP or enalapril, with no signiﬁcant
difference between these two groups (P = 1.000; Fig. 1B).
The combination of BNP and enalapril did not provide
additional beneﬁts in terms of survival rate during this
period. Rigorous monitoring combined with autopsy showed
that cardiac ruptures occurred within 7 days after MI (two
in the MI + enalapril group, two in the MI + BNP group, two
in the MI + combination group and three in the MI group)
with no differences between the four groups (P = 1.000,
respectively).
Tissue weight and percentage infarct
perimeter
There were no signiﬁcant differences in infarct perimeter
between the four MI groups at any time point post MI.
Neither enalapril nor BNP therapy exerted any protective
effects on infarct size (Table 1) and their combination did
not produce additive effects in terms of limiting infarct size.
The ratio of left ventricular weight/body weight
(LVW/BW) was markedly increased in the MI group compared
with the sham control group on day 28 post MI (P < 0.001),
and this increase in LVW/BW ratio was attenuated by both
enalapril (P = 0.024, vs. MI group) and BNP administration
(P = 0.002, vs. MI group). The combination of enalapril and
BNP showed a non-signiﬁcant trend towards producing a fur-
ther decrease in LVW/BW (P = 0.890, vs. MI + BNP group and
MI + Enalapril group, respectively).
Echocardiographic examination
At each time point, MI group rats had increased LVEDD com-
pared with sham controls (day 3, P = 0.002; day 7, P < 0.001
and day 28, P < 0.001), and within the MI group, the LV was
further dilated on day 28 compared with day 3 (P < 0.001).
Compared with the MI group, the increase in LVEDD on day
28 was attenuated by both enalapril (P = 0.033) and BNP
(P = 0.044) (Table 1).
Similarly, at each time point, MI group rats had lower FS
than sham controls (P < 0.001, respectively); within the MI
group, FS was further decreased on day 28 compared with on
day 3 (P = 0.004) and day 7 (P = 0.028). The beneﬁcial effects
of enalapril and BNP were only seen on day 28, indicated
by an increase in FS compared with the MI group on day
28 (MI + enalapril group, P = 0.036; MI + BNP group, P = 0.045;
Table 1).
However, the combination of enalapril and BNP only
showed a non-signiﬁcant trend towards further improve-
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ent in LV geometry and FS (P = 1.000, vs. MI+BNP group
nd MI + Enalapril group, respectively; Table 1).
aemodynamic variables
he heart rates of MI group rats were similar at each time
oint and were not different from those of the sham control
ats. Treatment with enalapril, BNP or combination ther-
py did not produce any changes in heart rate (data not
hown).
At each time point, MI group rats only showed a non-
igniﬁcant trend towards a decrease in MAP compared
ith sham controls. Both enalapril and combination ther-
py produced signiﬁcant decreases in MAP compared with
ham rats (day 3: enalapril group, P =0.005 and com-
ination group, P < 0.001; day 7: P < 0.001, respectively
nd day 28: enalapril group, P = 0.006 and combination
roup, P = 0.008). However, BNP produced a decrease
n MAP only on day 3 (P < 0.001, vs. sham controls)
Table 1).
Impaired LV function was also evidenced by an increase
n LVEDP at each time point in MI group rats, with a fur-
her increase within the MI group on day 28 (P < 0.001,
s. day 3 and day 7; respectively). Again, enalapril, BNP
nd combination therapy resulted in improved LVEDP only
n day 28 compared with the MI group (P < 0.001, respec-
ively). Combination therapy resulted in a further decrease
n LVEDP compared with the enalapril group alone (P = 0.017;
able 1).
ng II, cGMP and BNP concentrations
he concentration of Ang II was increased in MI group
ats compared with sham controls on day 3 (P < 0.001)
nd day 7 (P = 0.001) but had returned to a level similar
o that in sham controls on day 28. Enalapril treatment
esulted in decreases in Ang II concentration compared with
he MI group on day 3 (P = 0.006) and day 7 (P = 0.020);
owever, BNP infusion only showed a non-signiﬁcant trend
owards a reduction in Ang II (P = 0.115, vs. MI group) on
ay 3. Combination therapy achieved similar Ang II levels
s enalapril (P = 1.000, at each time point; respectively)
Fig. 2A).
MI group rats had similar cGMP concentrations to sham
ontrols at each time point (P = 1.000, respectively). A
igher concentration of cardiac cGMP was achieved by both
nalapril and BNP at each time point (P < 0.001 vs sham con-
rols, respectively), with no signiﬁcant differences between
hese two treatment groups at any time point. A further
ncrease was achieved when enalapril and BNP were com-
ined, but only on day 7 (P = 0.018, vs. MI + Enalapril group)
Fig. 2B).
BNP concentration was increased in MI group rats on day
compared with sham controls (P < 0.001), but decreased
radually to the level of sham controls on day 7 and day 28.
nalapril treatment did not affect BNP concentration signif-
cantly compared with MI group rats. By contrast, a higher
oncentration of BNP was achieved by chronic BNP infusion
hroughout the whole observation period compared with MI
roup rats. The combination therapy exerted an effect on
NP concentration that was similar to that achieved with
NP treatment alone (Fig. 2C).
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Table 1 Infarct perimeter, cardiac geometry, function and haemodynamic data for each group.
Observation period Groups IP (%) MAP (mmHg) LVEDP (mmHg) LVW/BW (mg/g) LVEDD (mm) FS (%)
3 days Sham — 114± 12 3.4± 1.0 1.76± 0.11 5.33± 0.33 61.7± 4.9
MI 38.35± 4.93 103± 10 8.3± 1.3a 1.89± 0.09 6.93± 0.92a 34.7± 9.3a
MI + enalapril 37.00± 3.45 95± 6a 8.9± 1.5a 1.91± 0.08 6.97± 0.37a 33.7± 12.2a
MI + BNP 39.13± 4.56 92± 5a 7.2± 0.9a 1.87± 0.06 7.20± 0.54a 37.2± 8.3a
Combination 38.27± 6.21 88± 5a,b 6.9± 1.0a 1.91± 0.07 7.10± 0.82a 38.6± 6.9a
7 days Sham — 114± 6 2.9± 0.8 1.76± 0.08 5.32± 0.338 60.3± 4.5
MI 42.10± 5.78 104± 7 10.2± 1.1a 1.93± 0.09 7.85± 0.58a 30.9± 6.6a
MI + enalapril 41.11± 7.33 93± 5a 8.4± 1.3a 1.86± 0.14 7.00± 0.53a 33.3± 6.1a
MI + BNP 42.13± 6.23 103± 8 7.2± 1.5a,b 1.89± 0.08 7.13± 0.63a 31.9± 7.0a
Combination 41.35± 3.46 92± 7a 6.5± 1.2a,b 1.85± 0.08 6.77± 0.54a,b 36.3± 4.4a
28 days Sham — 116± 12 2.8± 1.0 1.71± 0.13 5.68± 0.62 62.5± 4.2
MI 41.18± 5.92 106± 8 14.2± 1.7a,d,e 2.19± 0.12a 8.83± 0.61a,d 19.2± 2.6a,d,e
MI + enalapril 41.14± 6.25 96± 5a 9.5± 1.0a,b 1.90± 0.25b 7.47± 0.73a,b 27.7± 5.6a,b
MI + BNP 42.05± 6.08 104± 9 7.7± 1.2a,b 1.82± 0.11b 7.52± 0.97a,b 27.5± 3.9a,b
Combination 42.63± 7.31 97± 7a 6.8± 1.5a,b,c 1.75± 0.07b 6.92± 0.65a,b 31.4± 5.9a,b
All data are expressed as means± standard deviations. BNP: brain natriuretic peptide; FS: fractional shortening; IP: infarct perimeter; LVEDD: left ventricular end-diastolic diameter;
LVEDP: left ventricular end-diastolic pressure; LVW/BW: left ventricular weight/body weight; MAP: mean arterial pressures; MI: myocardial infarction.
a P < 0.05 vs sham control group at the same time point.
b P < 0.05 vs MI group at the same time point.
c P < 0.05 vs MI + enalapril group at the same time point.
d P < 0.05 vs MI group on day 3.
e P < 0.05 vs MI group on day 7.
Cardiac protection conferred by brain natriuretic peptides
Figure 2. Effects of BNP, enalapril and combination therapy on
Ang II (panel A), cGMP (panel B) and BNP (panel C) concentra-
tions in non-infarcted left ventricular tissue. All concentrations are
expressed as means± standard deviations. For comparison between
groups at the same time point: *P < 0.05 vs sham controls; §P < 0.05
vs MI group; ¶, P < 0.05 vs MI + enalapril group. For comparison within
the MI group: #P < 0.05 vs on day 3. Ang II: angiotensin II; BNP:
brain natriuretic peptide; cGMP: cyclic guanosine monophosphate;
MI: myocardial infarction.
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ctivation of nuclear factor NF-B and
ytokine levels
hosphorylation levels of the NF-B subunits IB, p50
nd p65 were enhanced in the non-infarcted LV of MI
roup rats on day 28 post-MI (P < 0.001, vs. sham controls;
espectively). However, both BNP and enalapril treatment
ttenuated phosphorylation levels of IB, p50, and p65
ompared with the MI group (P < 0.001, respectively) (Fig. 3).
The concentrations of TNF, IL-1 and IL-6 were increased
n the non-infarcted LV of MI rats on day 28 post-MI (P < 0.001,
s. sham controls; respectively), these were inhibited by
oth enalapril and BNP treatment (P < 0.001, vs. MI group;
espectively).
Combination therapy did not further suppress either the
hosphorylation levels of NF-B subunits (IB, P = 1.000;
50, P = 1.000 and p65, P = 0.853; vs. MI + Enalapril group,
espectively) or the expression levels of TNF and IL-6
P = 1.000 and P = 0.107, vs. MI + Enalapril group; respec-
ively). However, combination therapy did further suppress
he expression levels of IL-1 (P = 0.002 vs MI + enalapril
roup; P = 0.022 vs MI + BNP group).
MP-2/TIMP-1 and MMP-9/TIMP-1 protein
xpression ratios
n day 7, compared with MI group rats, there were signiﬁ-
ant decreases in both MMP-2/TIMP-1 and MMP-9/TIMP-1 in
nalapril-treated rats (P = 0.016 for MMP-2/TIMP-1; P = 0.001
or MMP-9/TIMP-1) but not in BNP-treated rats (P = 0.631
or MMP-2/TIMP-1; P = 1.000 for MMP-9/TIMP-1). Combi-
ation therapy only resulted in a non-signiﬁcant trend
owards further decreases in MMP-2/TIMP-1 and MMP-
/TIMP-1 (P = 0.672 and P = 1.000, vs. MI + Enalapril group;
espectively) (Fig. 4).
MP gelatinolytic activity
wo lytic bands were observed for MMP-2, one correspond-
ng to pro-MMP-2 (72 kDa) and the other to active-MMP-2
66 kDa). Another lytic band represented pro-MMP-9 (92 kDa)
ctivity (Fig. 5).
Compared with sham controls, pro-MMP-2 gelatinolytic
ctivity increased two-fold on day 3 and 2.7-fold on day 7 in
he non-infarcted area of MI group rats. Enalapril resulted
n decreases in pro-MMP-2 gelatinolytic activity on day 3
P = 0.015, vs. MI group) and day 7 (P < 0.001, vs. MI group),
hereas BNP treatment alone had no effect on MMP-2 gelati-
olytic activity. Combination therapy had similar effects to
nalapril on pro-MMP-2 gelatinolytic activity on day 3 and
ay 7. On day 28, pro-MMP-2 gelatinolytic activity was sim-
lar in all ﬁve groups (P > 0.05, respectively) (Fig. 5).
On day 3, the levels of pro-MMP-9 gelatinolytic activ-
ty were quite low in sham controls. In contrast, MI group
ats had a signiﬁcant increase in pro-MMP-9 activity (Fig. 5).
oth enalapril and combination therapy resulted in similar
ecreases in pro-MMP-9 gelatinolytic activity in non-infarct
V tissue compared with the MI group (enalapril group,
= 0.032; combination group, P = 0.020). Again, BNP infu-
ion alone had no effects on pro-MMP-9 gelatinolytic activity
P = 1.000, vs. MI group). MMP-9 activity was not detectable
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Figure 3. Representative bands for p-IB vs total IB (panel A), p-p65 subunit vs total p65 (panel B) and p-p50 subunit vs total p50
(panel C). The phosphorylation level of each subunit was then quantiﬁed and shown in a bar graph below, for each corresponding group.
The expression levels of TNF (panel D), IL-1 (panel E) and IL-6 (panel F) were also quantiﬁed in bar graphs. All data are expressed as
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n either day 7 or day 28 in non-infarcted LV tissue obtained
rom rats from any of the groups (Fig. 5).
ollagen quantiﬁcation
he infarct area showed no changes in CVF induced by MI
ompared with sham controls; CVF was not affected by
nalapril, BNP or combination therapy at any time point
P > 0.05, respectively) (Fig. 6A).
In non-infarcted LV tissue, MI group rats showed a gradual
ncrease in CVF (day 3 vs day 7, P = 0.047; day 7 vs day 28,
= 0.028). Both enalapril and BNP treatment improved CVF
n day 28 (P = 0.001, respectively) compared with MI group
ats. However, no further decrease in CVF was achieved
ith combination therapy (P = 0.740, vs. MI + Enalapril group)
Fig. 6B).
MI group rats also exhibited a time-course increase in col-
agen type I expression in non-infarcted LV tissue (day 3 vs
ay 7, P = 0.015; day 7 vs day 28, P = 0.003) compared with
ham controls. Both enalapril and BNP treatment resulted
i
a
t
B
aI group; ¶, P < 0.05 vs MI + enalapril group; P < 0.05 vs MI + BNP
etic peptide; GAPDH: glyceraldehyde 3-phosphate dehydrogenase;
ur necrosis factor.
n lower collagen type I expression on day 28 (P < 0.001,
espectively) compared with MI group rats, and a further
ecrease in collagen type I expression was observed only on
ay 28 when the two therapies were combined (P = 0.041,
s. MI + Enalapril group) (Fig. 6C).
Within the MI group, compared with on day 3, a similar
ncrease in collagen type III expression was present in non-
nfarcted LV tissue on day 7 (P = 0.013) and day 28 (P = 0.017).
owever, collagen type III expression was not affected by
nalapril, BNP or combination treatment (Fig. 6D).
iscussion
ur data demonstrate that chronic continuous BNP admin-
stration via an osmotic mini-pump after acute MI maintains
satisfactory BNP concentration in cardiac tissue, which, in
urn, increases the concentration of cGMP in heart tissue.
oth BNP infusion and enalapril administration were closely
ssociated with an attenuated phosphorylation level of the
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Figure 4. The representative bands for MMP-2, MMP-9 and TIMP-1 are shown in panel A for day 3, panel B for day 7 and panel C for day
28. The expression level was quantiﬁed by densitometry and normalized to that of -actin. The expression ratios were then calculated and
shown in a bar graph for both MMP-2/TIMP-1 (panel D) and MMP-9/TIMP-1 (panel E) for day 7. All data are expressed as means± standard
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NF-B subunits IB, p50 and p65, and hence lower expres-
sion of the cytokines TNF, IL-1 and IL-6 in non-infarcted heart
tissue. Improved collagen deposition was also observed in
non-infarcted areas. All these beneﬁts resulted in improved
cardiac geometry and performance, leading to improved sur-
vival rates during the 28-day observation period.
It is well established that inﬂammation is an important
pathophysiological process during the remodelling process.
Although appropriate inﬂammation is necessary for the heal-
ing process early after MI, overt and sustained inﬂammatory
responses induced by combined volume and pressure over-
load in the setting of signiﬁcant loss of myocytes can
eventually result in left ventricular dilation and dysfunction
[16]. NF-B, as a transcription factor, plays a key role in
mediating the inﬂammatory responses. A variety of stim-
uli, including ischaemia, oxidative stress and cytokines, can
activate NF-B, which, in turn, can induce further expres-
sion of pro-inﬂammatory cytokines [11]. It has been shown
that attenuation of NF-B activities can protect the heart
against cardiac hypertrophy and improve cardiac perfor-
mance in various pathological processes [17,18], especially
in the setting of MI [19—21]. However, the role of NF-B in
mediating the inﬂammatory reaction has been questioned
by a recent study in which p50 knock-out mice exhibited a
worse post-MI remodelling process [22], and the protective
role of NF-B was further demonstrated in another study
at the cellular level [23]. Our study has shown that the
improved cardiac remodelling process provided by BNP infu-
a
[
a
c
tMI + enalapril group;P < 0.05 vs MI + BNP group. ACEI: angiotensin-
al infarction; MMP: matrix metalloproteinase; TIMP: tissue inhibitor
ion and enalapril therapy was, in fact, associated with less
ctivation of the three NF-B subunits (IB, p50 and p65),
hus further supporting the idea that suppressed NF-B sig-
alling can protect the heart against the post-MI remodelling
rocess. The apparently different role for subunit p50 in the
nti-inﬂammatory process indicated in other studies could
e due to the different models or pharmacological agents
sed.
Intriguingly, in our study, although NF-B signalling acti-
ation was attenuated with BNP infusion, MMP-2 expression
nd MMP-9 expression were not decreased. In contrast,
nalapril administration resulted in a signiﬁcant decrease in
xpression of both MMP-2/TIMP-1 and MMP-9/TIMP-1 [24].
his is in striking contrast to previous data that have shown
hat MMP-9 is regulated by NF-B, as there is a binding site in
he promoter of the MMP-9 gene [25], indicating that a dif-
erent mechanism is involved in regulating MMP expression.
t has also been shown that transgenic mice overexpress-
ng BNP can induce MMP-9 expression [26]. Enhanced MMP
xpression and/or activity could potentially cause sudden
eath due to cardiac rupture [26,27]. Although MMP-2 may
xert a dual role in the post-MI remodelling process [28], in
hese studies, MMP-2 expression could only be induced at
−7 −6very high BNP concentration in vitro (∼10 —10 mol/L)
27], or at a plasma BNP concentration of 3× 10−9 mol/L,
s seen in BNP overexpression transgenic mice [26]. This
oncentration is much higher than the clinical therapeu-
ic concentration (8× 10−11 mol/L) [9] and the myocardial
26 Y. Pan et al.
Figure 5. The upper panel shows the representative zymographic imaging, with different bands to quantify the activities of MMPs. Pro-MMP-
9, pro-MMP-2 and active MMP-2 are shown at 92 kDa, 72 kDa and 66 kDa, respectively. Bar graphs in the lower panel demonstrate the activity of
pro-MMP-2 at different time points (left) and the activity of pro-MMP-9 on day 3 (right). All data are expressed as means± standard deviations.
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issue BNP concentration in our present study. Therefore,
his side effect might only be seen at an extremely high
ose of BNP in the clinical setting. In fact, cardiac rupture
as not reported in either of the earlier clinical trials or in
nimal experiments in the setting of MI, although BNP was
nly given for 60 hours to patients with MI [9] or was deliv-
red once-a-day in a rat MI model [10]. In our present study,
NP was continuously delivered via an osmotic mini-pump
mplanted intraperitoneally throughout the whole observa-
ion period. Therefore, the cardiac BNP concentration was
aintained at a stable level. Neither expression nor activ-
ty of MMP-2 and MMP-9 was signiﬁcantly increased by BNP
nfusion, and no increased incidence of cardiac rupture was
bserved with our rigorous monitoring protocol. Therefore,
ur data conﬁrmed that continuous BNP infusion does not
nduce a signiﬁcant increase in MMP-9 and MMP-2 expression,
nd does not result in cardiac rupture.
In addition, it has been shown that activation of
he TGF1/Smad2 signalling pathway can be activated
y Ang II, and results in collagen deposition and ﬁbro-
is [29,30]. In cell cultures of human ﬁbroblasts, BNP
dministration can increase the cGMP concentration and
ence inhibit TGF/Smad2 signalling, while activating
he mitogen-activated protein kinase/extracellular signal-
egulated kinase pathway [31]. This protective effect was
lso observed in an in vivo rat MI model, by the inhibi-
B
e
a
i
tham controls; §P < 0.05 vs MI group; ¶, P < 0.05 vs MI + enalapril
uretic peptide; C: MI control group; E: MI + enalapril group; E + B:
roteinase; S: sham control group.
ion of TGF1/Smad2 signalling [10]. Our data show that
NP infusion can attenuate the proinﬂammatory responses
ia inactivation of NF-B, which, in turn, can suppress the
xpression level of proinﬂammatory cytokines and hence
nhibit TGF1/Smad2 signalling. However, it is still not
nderstood why the Ang II expression level was not affected
y BNP infusion, indicating that a different pathway is
nvolved in regulating Ang II expression; further study is
herefore certainly warranted.
imitations
here are conﬂicting data in our study regarding the mech-
nisms via which BNP therapy improved the remodelling
rocess. First, Ang II expression was not affected by BNP
nfusion, which contradicts the fact that NF-B activation
s attenuated. Second, BNP concentration was not affected
y enalapril therapy although cardiac function was signiﬁ-
antly improved. Third, MMP expression and/or activities in
he non-infarcted area were also differentially modulated by
NP and enalapril. In the present study, we are not able to
lucidate the underlying mechanisms by which BNP might
ct differently from enalapril. We reason that these data
ndicate that different mechanisms are involved in the two
reatments in the setting of MI. In addition, the moderate
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Figure 6. The effects of BNP and enalapril on CVF were quantiﬁed in the infarct area (panel A) and in non-infarcted left ventricular tissue
(panel B). In non-infarcted left ventricular tissue, both collagen type I (panel C) and collagen type III (panel D) content were also quantiﬁed.
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MI: myocardial infarction.
infarct size we selected could potentially mask the pre-
dictive role regarding prognosis when enalapril was given.
In addition, we cannot fully exclude that the improved
remodelling process is due to improved haemodynamic sta-
sis, such as vasodilatation effects of BNP infusion. However,
the long-term beneﬁcial effect on the remodelling process
(independent of the infarct size sparing effects) of vasodi-
lating drugs such as nitrites is still not fully established [32];
they could eventually be found to exert a protective effect
via anti-inﬂammatory effects, as shown in the present study.
Conclusion
BNP infusion can increase the cGMP concentration in cardiac
tissue and protect against adverse LV remodelling, resulting
in similar effects as angiotensin-converting enzyme inhibitor
treatment. The improved remodelling process is closely
associated with attenuation of NF-B activation. Further
study is warranted to elucidate the underlying mechanismscontrols; §P < 0.05 vs MI group; ¶, P < 0.05 vs MI + enalapril group.
7. BNP: brain natriuretic peptide; CVF: collagen volume fraction;
y which Ang II expression is differentially regulated by
NP infusion and angiotensin-converting enzyme inhibitors,
specially the link between inhibition of NFB and the
GF1/Smad2 pathways during the post-MI remodelling pro-
ess.
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